P2‐099: a tale of two provinces: comparison of the successes and challenges of structured, stepwise development in two canadian provincial research and evaluation imbedded hcv elimination strategies (English)
In:
JOURNAL OF VIRAL HEPATITIS
;
25
;
NA
;
2018
-
ISSN:
- Article (Journal) / Print
-
Title:P2‐099: a tale of two provinces: comparison of the successes and challenges of structured, stepwise development in two canadian provincial research and evaluation imbedded hcv elimination strategies
-
Published in:JOURNAL OF VIRAL HEPATITIS ; 25 ; NA
-
Publisher:
- New search for: Wiley-Blackwell
-
Publication date:2018-01-01
-
Size:NA
-
ISSN:
-
Type of media:Article (Journal)
-
Type of material:Print
-
Language:English
- New search for: 616.3623
- Further information on Dewey Decimal Classification
-
Classification:
DDC: 616.3623 -
Source:
© Metadata Copyright the British Library Board and other contributors. All rights reserved.
Table of contents – Volume 25
The tables of contents are generated automatically and are based on the data records of the individual contributions available in the index of the TIB portal. The display of the Tables of Contents may therefore be incomplete.
- 1
-
Issue Information| 2018
- 4
-
Immunotherapy for hepatitis b in the direct acting antiviral era: reevaluating the thymosin α1 efficacy trials in the light of a combination therapy approachNaylor, P. H. / Mutchnick, M. G. et al. | 2018
- 6
-
Hepatitis c: the beginning of the end—key elements for successful european and national strategies to eliminate hcv in europePapatheodoridis, G. V. / Hatzakis, A. / Cholongitas, E. / Baptista‐Leite, R. / Baskozos, I. / Chhatwal, J. / Colombo, M. / Cortez‐Pinto, H. / Craxi, A. / Goldberg, D. et al. | 2018
- 6
-
O‐002: Genetic variability of hepatitis C quasi‐species in early infection| 2018
- 6
-
O‐001: Investigation of the molecular mechanisms that determine isolate‐specific differences in neutralization sensitivity of HCV| 2018
- 7
-
O‐004: HBV RNA in serum is an early predictor for sustained immune control following treatment with pegylated interferon alfa in patients with HBeAg negative chronic hepatitis B and its relation to other serum viral biomarkers| 2018
- 7
-
O‐005: Hepatitis E – profile and predictors of mortality: Indian experience| 2018
- 8
-
O‐006: Association between liver fibrosis and HEV seroprevalence among HIV‐positive individuals in Nepal| 2018
- 8
-
O‐007: Expansion of HCV‐specific T cells with a follicular T helper cell phenotype after DAA mediated antigen removal| 2018
- 9
-
O‐009: A novel gene immunotherapy for chronic HBV and HDV: blocking viral entry by neutralizing PreS1 antibodies| 2018
- 9
-
O‐008: Differential peripheral immune responses during DAA treatment in HCV patients that develop HCC| 2018
- 10
-
On the potential of a short‐term intensive intervention to interrupt hcv transmission in hiv‐positive men who have sex with men: a mathematical modelling studySalazar‐Vizcaya, L. / Kouyos, R. D. / Fehr, J. / Braun, D. / Estill, J. / Bernasconi, E. / Delaloye, J. / Stöckle, M. / Schmid, P. / Rougemont, M. et al. | 2018
- 10
-
O‐012: Is hepatitis C elimination possible among HIV‐infected population in Canada?| 2018
- 10
-
O‐010: A phase 2 dose‐optimization study of lonafarnib with ritonavir for the treatment of chronic delta hepatitis—analysis from the LOWR HDV‐2 study using the robogene® real‐time qPCR HDV RNA assay| 2018
- 11
-
O‐013: Hepatic fibrosis measured by elastography among HIV‐infected and HIV‐uninfected people who inject drugs (PWID)| 2018
- 12
-
O‐014: Correlates of hepatic fibrosis among HIV‐infected individuals from an urban infectious disease clinic in East Africa| 2018
- 12
-
O‐015: Combination treatment of a TLR7 agonist RO7020531 and a capsid assembly modulator RO7049389 achieved sustainable viral load suppression and HBsAg loss in an AAV‐HBV mouse model| 2018
- 13
-
O‐017: An immunochromatographic test for measurement of alanine aminotransferase 1 (ALT1) at point‐of‐care| 2018
- 13
-
O‐016: Interferon‐gamma pathway is activated in a chronically HBV infected chimpanzee that controls HBV following ARC‐520 RNAi treatment| 2018
- 14
-
O‐020: Origin and function of secreted ORF2 in hepatitis E virus infection| 2018
- 14
-
O‐018: Updated Follow‐up Analysis in the REP 401 Protocol: Treatment of HBeAg Negative Chronic HBV Infection with REP 2139 or REP 2165, Tenofovir Disoproxil Fumarate and Pegylated Interferon α‐2a| 2018
- 14
-
O‐021: Antiviral CD4+ but not CD8+ T cell immunity is required to prevent hepatitis E virus persistence| 2018
- 15
-
O‐022: Economic analysis of Egypt’s hepatitis C control policies| 2018
- 16
-
O‐024: A novel CRISPR/Cas9‐based approach to transient activation of intracellular host restriction factors results in strong suppression of hepatitis B virus and degradation of cccDNA| 2018
- 16
-
O‐023: Pathways to ensure universal and affordable access to hepatitis C treatment| 2018
- 17
-
O‐025: Identification of ISG20 as the Nuclease involved in Interferon‐induced Decline of HBV cccDNA| 2018
- 17
-
O‐026: Kupffer cells coordinate interferon‐lambda driven inflammation| 2018
- 18
-
O‐027: Sex‐linked Variation in Immune Cell Composition and Inflammatory Potential in the Human Liver| 2018
- 18
-
O‐028: Directly acting antiviral HCV therapy is safe and effective in patients with advanced cirrhosis: real world experience from the HCV‐TARGET cohort| 2018
- 19
-
Gsk2878175, a pan‐genotypic non‐nucleoside ns5b polymerase inhibitor, in healthy and treatment‐naïve chronic hepatitis c subjectsGardner, S. D. / Kim, J. / Baptiste‐Brown, S. / Lopez, V. / Hamatake, R. / Gan, J. / Edwards, S. / Elko‐Simms, L. / Dumont, E. F. / Leivers, M. et al. | 2018
- 19
-
O‐029: Analysis of AST to platelet ratio index (APRI) for determining eligibility for 8 weeks of glecaprevir/pibrentasvir| 2018
- 20
-
O‐030: Early hepatitis C virus and IP‐10 kinetics during DAA treatment with sofosbuvir, velpatasvir, and voxilaprevir in HCV mono‐infected and HIV/HCV co‐infected persons| 2018
- 21
-
O‐031: Are hepatitis delta virus (HDV) genotypes important to determine the disease progression and therapy responses?| 2018
- 21
-
O‐033: Histologic predictors of liver‐related outcomes and mortality in patients with chronic hepatitis B and non‐alcoholic fatty liver disease| 2018
- 22
-
O‐035: Early function modulation and reprogramming of liver resident and infiltrating macrophages promote the establishment of HBV infection| 2018
- 22
-
O‐034: A decisive role of target cells during antiviral immunity in the liver| 2018
- 23
-
O‐036: Comparison of event‐free survival between DAA and IFN‐based antiviral therapy for HCV, adjusted for disease severity| 2018
- 24
-
O‐037: Genotype 5 HCV – patient characteristics, resistance mutations and treatment outcomes| 2018
- 24
-
O‐038: Prevention and care cascade for hepatitis C among people who inject drugs in British Columbia, Canada| 2018
- 25
-
O‐040: The global impact of direct acting antivirals on hepatitis C virus burden: a ten‐year forecast| 2018
- 25
-
O‐039: Extension of hepatitis C screening, diagnosis and treatment into the community: a low cost, point of care, test and treat model for Pakistan| 2018
- 26
-
O‐041: Global scale‐up of hepatitis C interventions will reduce burden but not eliminate the disease| 2018
- 27
-
O‐044: Low serum HBsAg and HBV DNA levels identify strongest responders of pegylated interferon addition to entecavir in HBeAg positive chronic hepatitis B| 2018
- 27
-
O‐043: Safety and efficacy at 1 year after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in chronic HBV patients with risk factors for TDF use| 2018
- 28
-
Drug use and phylogenetic clustering of hepatitis c virus infection among people who use drugs in vancouver, canada: a latent class analysis approachJacka, B. / Bray, B. C. / Applegate, T. L. / Marshall, B. D. L. / Lima, V. D. / Hayashi, K. / DeBeck, K. / Raghwani, J. / Harrigan, P. R. / Krajden, M. et al. | 2018
- 28
-
O‐045: Increasing hepatitis C testing uptake with point of care testing from the needle and syringe exchange desk – lessons learned from the Rapid‐EC Feasibility Study| 2018
- 29
-
O‐046; Immunological phenotyping of HLA‐restricted HBV specific T cell responses in dually humanized mice| 2018
- 29
-
O‐047: Sustained off‐treatment response is associated with HBsAg loss following Nucleos(t)ide Analogue induced HBeAg seroconversion| 2018
- 30
-
O‐049: Elimination of hepatitis C as a public health threat. The Treatment as Prevention (TraP HepC) program in Iceland, milestones and remaining challenges| 2018
- 30
-
O‐048: Clinical and virological predictors of response after antiviral therapy interruption in HBeAg‐negative chronic hepatitis B| 2018
- 31
-
O‐050: Drug and alcohol use patterns during and following treatment with sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use: Insights from trajectory analyses| 2018
- 32
-
O‐051: Cost‐effectiveness of the controlled temperature chain for the hepatitis B birth dose vaccine in a variety of global settings| 2018
- 32
-
O‐052: Hepatitis A outbreak in men having sex with men in Israel 2017: environmental and clinical surveillance| 2018
- 34
-
P1‐002: Dysfunctional HBsAg‐specific and modified global B cells in chronic Hepatitis B virus infection| 2018
- 34
-
P1‐001: Non‐cytolytic T‐cell receptor‐redirected T cells limit HBV infection through activation of APOBEC3| 2018
- 35
-
P1‐003: The impact of HBsAg on general and HBV‐specific immunity| 2018
- 36
-
P1‐005: Hepatitis B virus escapes non‐canonical CTL effector function| 2018
- 36
-
P1‐004: Safety, pharmacokinetics and antiviral activity of novel capsid assembly modulator (CAM) JNJ‐56136379 (JNJ‐6379) in treatment‐naïve chronic hepatitis B (CHB) patients without cirrhosis| 2018
- 37
-
P1‐007: Abstract withdrawn.| 2018
- 37
-
Directly observed therapy of sofosbuvir/ribavirin +/− peginterferon with minimal monitoring for the treatment of chronic hepatitis c in people with a history of drug use in chennai, india (c‐dot)Solomon, S. S. / Sulkowski, M. S. / Amrose, P. / Srikrishnan, A. K. / McFall, A. M. / Ramasamy, B. / Kumar, M. S. / Anand, S. / Thomas, D. L. / Mehta, S. H. et al. | 2018
- 37
-
P1‐008: Retrotransposon elements are among initial sites of hepatitis B virus integration into human genome| 2018
- 38
-
P1‐011: Estimates and projection of disease burden and economic analysis for hepatitis B in Viet Nam| 2018
- 39
-
P1‐012: Surface engineered vesicular carriers for transmucosal immunization via the nasal route| 2018
- 39
-
P1‐014: Preclinical in‐vivo characterization of an oral TLR7 agonist, AL‐034 (or TQ‐A3334)| 2018
- 40
-
P1‐015: Oral administration of JNJ‐4964 (AL‐034/TQ‐A3334), a selective toll‐like receptor 7 agonist, in AAV/HBV mice for 12 weeks, resulted in potent and sustained anti‐HBV activity with HBsAg seroconversion and detectable HBsAg‐specific T cells and B cells| 2018
- 40
-
P1‐017: Ground glass hepatocytes provide targets for prevention and therapy of HBV‐related hepatocellular carcinoma| 2018
- 41
-
P1‐018: Enhanced ex vivo detection of HBV‐specific T cells| 2018
- 41
-
P1‐021: Development and characterization of oral combination vaccine against Hepatitis B & Anthrax| 2018
- 42
-
P1‐022: Development of nanoparticulate system for vaccine delivery| 2018
- 42
-
P1‐023: Noninvasive topical immunization using cholera toxin as adjuvant for the treatment of hepatitis B| 2018
- 43
-
P1‐024: Global scientific strategy for an HBV cure| 2018
- 43
-
P1‐026: Electricity free point‐of‐care viral hepatitis testing for resource poor country via ultra‐low cost blood centrifugation using paper/plastic: a pilot study| 2018
- 44
-
P1‐029: Peripheral NK cell frequency and functionality in the context of the chronic HCV mono‐ and HCV/HIC co‐infection| 2018
- 44
-
P1‐030: Comparative expression profiling of serum microRNA‐21 in hepatitis B virus‐associated chronic hepatitis, liver cirrhosis and hepatocellular carcinoma patients| 2018
- 45
-
P1‐037: Role of interleukin 28B polymorphism in response to interferon based therapy for hepatitis C virus clearance in Libya| 2018
- 45
-
P1‐031: Effects of resistance‐associated variants on NS5B polymerase structure of Hepatitis C virus genotype 1b| 2018
- 46
-
P1‐039: TLR7 agonist RO7020531 triggers repeated immune activation after multiple doses in healthy volunteers| 2018
- 46
-
P1‐040: RO7049389, a core protein allosteric modulator, is safe and well tolerated in healthy volunteers and demonstrates potent anti‐HBV activity in a phase 1 trial| 2018
- 47
-
Hepatocellular carcinoma in patients with chronic hepatitis c and cirrhosis in denmark: a nationwide cohort studyHallager, S. / Ladelund, S. / Kjær, M. / Madsen, L. G. / Belard, E. / Laursen, A. L. / Gerstoft, J. / Røge, B. T. / Grønbæk, K. E. / Krarup, H. B. et al. | 2018
- 47
-
P1‐041: Generating CD4+ T cells for the T‐cell therapy of HBV infection| 2018
- 47
-
P1‐042: Next generation sequencing identifies baseline T1753V and A1762T/G1764A variants as unfavorable predictors of pegylated interferon therapy in HBeAg‐positive chronic hepatitis B| 2018
- 48
-
P1‐045: Treatment of chronic hepatitis B with nucleoside analogues in cirrhotic patients at Yalgado Ouedraogo University Hospital Center of Ouagadougou: about 38 cases| 2018
- 48
-
P1‐044: Hepatitis B virus therapy with nucleos(t)ide analogues significantly reduces fibrosis in a ‘Real‐world’ Canadian cohort| 2018
- 49
-
P1‐047: Natural history of 647 cases of acute hepatitis B in a reference viral hepatitis clinic: 20 years of follow‐up| 2018
- 49
-
P1‐049: Plasma B‐cell activating factor levels and polymorphisms in hepatitis B‐related hepatocellular carcinoma: clinical correlation and prognosis| 2018
- 50
-
P1‐052: Expression of metastatic tumor antigen 1 correlates with tumor and clinical features of patients with hepatitis B virus‐related hepatocellular carcinoma| 2018
- 50
-
P1‐053: Assessment of health‐related quality of life in patients with chronic hepatitis B| 2018
- 51
-
P1‐054: Evaluation of the effectiveness of Hepatitis B (HB) vaccination of newborns from HBsAg‐positive mothers followed by the national enlarged vaccination program including HB in the district health of Tokombéré, Cameroon| 2018
- 51
-
P1‐055: Development of a prototype lateral flow immunoassay for the rapid detection of hepatitis B virus core‐related antigen| 2018
- 52
-
P1‐056: Altered HBV‐specific CD4+ T‐cell Responses in HBV/HIV‐1 Co‐ versus HBV Mono‐infected Patients| 2018
- 53
-
P1‐059: Vitamin D levels and polymorphism of vitamin D receptor (VDR) were not associated to laboratorial data among hepatitis B virus (HBV) patients| 2018
- 53
-
P1‐060: Prevalence and risk factor of Helicobacter pylori in Beninese patients with chronic hepatitis B| 2018
- 53
-
P1‐061: Age and Helicobacter pylori infection: risk factors of alanine aminotransferase elevation in chronic hepatitis B carriers in Benin| 2018
- 54
-
P1‐062: High efficacy of HCV therapy following universal DAA access in Australia: the REACH‐C cohort| 2018
- 54
-
P1‐063: Effectiveness of elbasvir/grazoprevir in patients with chronic hepatitis C and chronic kidney disease: results from the veterans affairs system| 2018
- 55
-
P1‐064: An independent analysis of 43 758 adverse drug reactions relating to the new hepatitis C direct acting antivirals submitted to the FDA FAERS reporting system between April 2014 and September 2017| 2018
- 55
-
P1‐065: HCV RAS testing and genotyping by NGS: a 2nd generation automated workflow| 2018
- 56
-
P1‐066: Telemedicine outcomes in the hepatitis C direct acting antiviral era| 2018
- 56
-
A different perspective on sofosbuvir‐ledipasvir treatment of patients with hcv genotype 1b cirrhosis: the ital‐c network studyBarone, M. / Iannone, A. / Shahini, E. / Ippolito, A. M. / Brancaccio, G. / Morisco, F. / Milella, M. / Messina, V. / Smedile, A. / Conti, F. et al. | 2018
- 56
-
P1‐067: Efficacy and safety of elbasvir/grazoprevir in women infected with hepatitis C virus genotype 1 or 4 and co‐administered oral contraceptives or hormone replacement therapy| 2018
- 57
-
P1‐068: Hepatitis C treatment with Ledipasvir and Sofosbuvir in a low socioeconomic population at a Federally Qualified Health Center [FQHC]| 2018
- 58
-
P1‐069: Modeling time to cure after short‐duration treatment for chronic HCV with daclatasvir, asunaprevir, beclabuvir and sofosbuvir: the FOURward study| 2018
- 58
-
P1‐070: Hepatitis C care cascade among an insured population, 2010–2015: gaps to elimination| 2018
- 59
-
P1‐071: Efficacy of Ledipasvir/Sofosbuvir in Egyptian adolescents with hepatitis C virus genotype 4; a single center study| 2018
- 59
-
P1‐072: Systematic review and meta‐analysis of sustained viral response to hepatitis C direct‐acting antiviral therapy in people who currently inject drugs| 2018
- 60
-
P1‐074: High HCV cure rates with primary care‐based HCV treatment in an urban health center| 2018
- 60
-
P1‐073: Sharing the cure: a comprehensive hepatitis C training program for primary care clinicians| 2018
- 61
-
P1‐076: The clinical outcome and safety of generic DAA treatment for HCV infection in Vietnam in 2016| 2018
- 61
-
P1‐075: HCC recurrence in HCV patients after liver transplantation in the DAA treatment era: SiLVER Study subgroup analysis reveals sirolimus treatment in combination with CNIs is an excellent treatment option| 2018
- 62
-
P1‐078: Efficacy and safety of pan‐genotypic direct acting antivirals (DAAs) in genotype 3 chronic hepatitis C (CHC): a systematic review and meta‐analysis| 2018
- 62
-
P1‐077: Chronic hepatitis C treatment in prison settings: eradication model for difficult to reach populations| 2018
- 63
-
P1‐079: Liver fibrosis regression after HCV treatment with direct acting antivirals in a community‐based population| 2018
- 63
-
Claudin‐1, mir‐122 and apolipoprotein e transductions improve the permissivity of snu‐182, snu‐398 and snu‐449 hepatoma cells to hepatitis c virusFournier, C. / Hoffmann, T. W. / Morel, V. / Descamps, V. / Dubuisson, J. / Brochot, E. / Francois, C. / Duverlie, G. / Castelain, S. / Helle, F. et al. | 2018
- 63
-
P1‐080: Prevalence of baseline NS5A resistance associated sequences (RAS) in treatment naïve patients with genotype 1 and 3 in Canada| 2018
- 64
-
P1‐082: Which cure is safest? Systematic review and network meta‐analysis of the safety of direct acting antiviral therapy for hepatitis C| 2018
- 65
-
P1‐084: Risk of hepatocellular carcinoma recurrence in patients treated with direct acting antivirals in real world setting| 2018
- 66
-
P1‐085: Utilization and effectiveness of Elbasvir/Grazoprevir (EBR/GZR) in treatment Naïve (TN) genotype 1a (G1a) chronic hepatitis C virus (HCV) patients with/without baseline NS5A resistance‐associated substitutions (RASs)| 2018
- 66
-
P1‐086: Effect of vitamin D on treatment response in chronic hepatitis C patients: a propensity score stratification and multilevel analysis| 2018
- 67
-
P1‐087: Real world experience of sofosbuvir‐based HCV treatment in Alaska Native/American Indian (AN/AI) persons living in Alaska: the Alaska hepatitis C cohort (AK‐HepC)| 2018
- 68
-
P1‐088: Z‐PROFILE: real‐world utilization and effectiveness of Elbasvir/Grazoprevir in adult patients with chronic hepatitis C in Canada – final study results| 2018
- 69
-
P1‐090: Efficacy and safety of Glecaprevir/Pibrentasvir in patients with metabolic syndrome and HCV infection: an integrated analysis| 2018
- 69
-
P1‐089: Hepatocellular carcinoma occurrence and recurrence during and post direct acting antiviral treatments of real‐life chronic hepatitis C patients in Mongolia| 2018
- 70
-
P1‐091: Treatment rates and toxicity for Hodgkin disease associated with viral hepatitis C and HIV| 2018
- 71
-
P1‐093: Paritaprevir/Ritonavir/Ombitasvir plus Dasabuvir regimen in the treatment of genotype 1 chronic hepatitis C infection in kidney transplant candidates.| 2018
- 71
-
P1‐092: The efficacy of sofosbuvir/velpatasvir/ribavirin in cirrhotic, genotype 3a HCV patients, previously failures to sofosbuvir/daclatasvir/ribavirin combination| 2018
- 72
-
P1‐094: Immediate direct‐acting antiviral therapy (DAA) of recurrent HCV infection after liver transplantation improves post‐transplant survival: single center experience (2014–2017)| 2018
- 72
-
Hbv reactivation in patients with hcv/hbv cirrhosis on treatment with direct‐acting antiviralsCalvaruso, V. / Ferraro, D. / Licata, A. / Bavetta, M. G. / Petta, S. / Bronte, F. / Colomba, G. / Craxì, A. / Di Marco, V. et al. | 2018
- 72
-
P1‐095: Virological responses & liver functions in patients with HCV related cirrhosis after treatment with directly acting antivirals (DAAs), a real life experience from a tertiary care center in India| 2018
- 73
-
P1‐096: Eradication of chronic hepatitis C infection with direct acting antivirals is associated with reduction in fibrosis by Transient Elastography (FibroScan)| 2018
- 73
-
P1‐097: Hepatitis C direct‐acting antiviral treatment failures: clinical characteristics and resistance testing from a real‐world setting| 2018
- 74
-
P1‐100: A real life study on treatment of HIV/HCV genotype IV coinfection with directly acting antiviral drugs (Egyptian Cohort)| 2018
- 74
-
P1‐098: Patient‐reported quality of life improves after treatment of hepatitis C with direct‐acting anti‐virals: a real‐world experience| 2018
- 75
-
P1‐101: A descriptive analysis of the effectiveness of direct acting antiviral therapies at achieving SVR12 in chronic HCV patients with various comorbidities and characteristics in NB| 2018
- 75
-
P1‐102: Effectiveness and utilization of elbasvir/grazoprevir in HCV genotype 1 and 4 infection in the veteran affairs healthcare system in the United States| 2018
- 76
-
P1‐103: Use of medications with clinically important drug‐drug interactions (DDIS) with direct‐acting antivirals (DAAS) for the treatment of chronic hepatitis C (CHC) infection: focus on ethinyl estradiol and HMG‐CoA reductase inhibitors| 2018
- 77
-
P1‐105: Real life data about sofosbuvir, daclatasvir and ribavirin in the treatment of cirrhotic and non cirrhotic HCV patients| 2018
- 77
-
P1‐104: Effectiveness of elbasvir/grazoprevir in persons with cirrhotic genotype 1 or 4 chronic hepatitis C: updated retrospective data analyses from the trio network| 2018
- 78
-
P1‐107: Safety and efficacy of direct acting antivirals in genotype 4 chronic hepatitis C elderly patients, a pilot study| 2018
- 78
-
P1‐106: Very high efficacy and safety of daas in pwid with chronic hepatitis c on opiate substitution treatment with buprenorphine: real life data from central Greece| 2018
- 79
-
P1‐110: Chronic HCV‐infection therapy and micro‐RNA‐122, micro‐RNA‐199a, micro‐ RNA‐196, micro‐RNA‐491 and micro‐RNA‐16| 2018
- 79
-
P1‐111: HCV treatment prioritization in corrections| 2018
- 80
-
P1‐112: Efficacy and safety of elbasvir/grazoprevir (EBR/GZR) in people with hepatitis C virus (HCV) infection aged 35 years or younger| 2018
- 80
-
Can quantitative hepatitis b surface antigen levels predict the severity of liver disease in genotype e patients?Chakrabarty, Gayatri / Bruce, Matthew / Horner, Mary / Wang, Bo / Agarwal, Kosh / Carey, Ivana et al. | 2018
- 81
-
P1‐113: Longitudinal analysis of HCV full genomes in patients failing NS5A inhibitors reveals the selection of novel amino acid substitutions outside NS5A| 2018
- 82
-
P1‐115: Evaluation of ankle‐arm index and clinical markers of vascular disease in patients with hepatitis C before and after DAA treatments| 2018
- 82
-
P1‐114: Seroconversion of Hepatitis C during dialysis in Major cities of Pakistan| 2018
- 85
-
P1‐117: Profile of hepatitis C core protein (R70Q and L91M) associated with cirrhosis/Hepatocarcinogenesis and the therapeutic response| 2018
- 85
-
P1‐116: An up‐date of the distribution of hepatitis C virus genotypes. Ten years of experience| 2018
- 86
-
P1‐118: Dyspepsia in Cirrhotic Hepatitis C Patients| 2018
- 86
-
P1‐119: Development of the new software pyroedit to quantify editing rate of the hepatitis delta virus RNA: preliminary results on clinical samples| 2018
- 87
-
P1‐121: Evaluation of peripheral immune response during acute cholestatic Hepatitis E infection| 2018
- 87
-
P1‐120: Prevalence of acute hepatitis e infection in community: a cross sectional cohort study in New York| 2018
- 88
-
P1‐122: Circulation of two european hepatitis a genotype IA outbreak strains among men who have sex with men in Brazil| 2018
- 88
-
The epidemiology of hepatitis b virus infection in women of reproductive age in highly endemic areas in chinaZheng, H. / Cui, F. Q. / Wang, F. Z. / Huang, L. F. / Shao, X. P. / Du, J. F. / Li, J. / Zhou, Y. / Zheng, H. Z. / Zhuo, J. T. et al. | 2018
- 89
-
P1‐123: Comparison of hepatitis delta and HBV monoinfection in a real‐world setting| 2018
- 89
-
P1‐124: Does hepatic involvement affect outcome in dengue Infection?| 2018
- 90
-
P1‐125: Prevalence of antiHEV IgG in Argentina: high geographic variation| 2018
- 90
-
P1‐126: Chronic hepatitis C among patients diagnosed with B‐Non‐Hodgkin lymphoma| 2018
- 91
-
P1‐129: Severe chronic hepatitis in a young immunossupressed Brazilian patient co‐infected with Hepatitis E Virus (HEV) and Epstein‐Barr Virus (EBV): a case report| 2018
- 91
-
P1‐127: Seroprevalence of hepatitis E virus in Machala, Ecuador| 2018
- 92
-
P1‐130: Efficient dried blood spot‐based determination of Hepatitis B seroprevalence from a national survey in the democratic republic of the congo| 2018
- 93
-
P1‐131: Findings from a novel hepatitis B surveillance system in the Australian state of Victoria, 2011–2016| 2018
- 93
-
P1‐132: Risk factor for acquiring Hepatitis B and C virus infection among HIV infected individuals in Nepal| 2018
- 94
-
P1‐134: Contribution of hepatitis D virus infection to risk of cirrhosis and hepatocellular carcinoma in the Gambia| 2018
- 94
-
P1‐133: Very late diagnosis of chronic hepatitis B infection| 2018
- 95
-
P1‐135: Molecular detection of Hepatitis B virus (HBV) DNA among Hepatitis B Surface antigen (HBsAg) Negative Blood Donors in Angola| 2018
- 96
-
P1‐137: Lack of prenatal HBV and HCV screening and follow‐up in Ontario, Canada| 2018
- 96
-
P1‐136: Creating evidence basis to monitor progress of viral hepatitis elimination goals in Germany| 2018
- 97
-
P1‐139: Viral hepatitis and schistosomiasis as risk factors for hepatocellular carcinoma| 2018
- 97
-
P1‐138: Variations in specialist referral patterns for inactive chronic hepatitis B by general practice characteristics in Australia| 2018
- 97
-
Inverse relationship between hepatic steatosis and hepatitis b viremia: results of a large case‐control studyHui, R. W. H. / Seto, W.‐K. / Cheung, K.‐S. / Mak, L.‐Y. / Liu, K. S. H. / Fung, J. / Wong, D. K.‐H. / Lai, C.‐L. / Yuen, M.‐F. et al. | 2018
- 98
-
P1‐141: Impact of late hepatitis B immunization in Angola| 2018
- 98
-
P1‐140: Evaluation of dried blood spot samples for detecting hepatitis B virus genotypes| 2018
- 99
-
P1‐144: Hepatitis B: changes in epidemiological and molecular features of afro‐brazilian communities| 2018
- 99
-
P1‐145: Could we avoid percutaneous liver biopsies in chronic hepatitis B? Insights from a new combined predicting model of significant fibrosis| 2018
- 100
-
P1‐147: Prevalence and predictors of complementary and alternative medicine use in a migrant‐rich chronic hepatitis B population: socio‐economics are more important than ethnicity| 2018
- 100
-
P1‐146: Viral hepatitis B and C among manual sugar cane cutters in Brazil: a community‐based study| 2018
- 101
-
P1‐149: Health‐related quality of life in patients with chronic hepatitis B: Influence of treatment| 2018
- 101
-
P1‐148: Genetic diversity of the hepatitis B virus in Brazil| 2018
- 102
-
P1‐150: Evaluation of hepatitis B core antibody detection using oral fluid samples according to background prevalence| 2018
- 102
-
P1‐151: Characteristics of People Diagnosed with Acute and Chronic Hepatitis B Virus Infection Differ by Ethnicity| 2018
- 103
-
P1‐152: Development and evaluation of a crowdsourced intervention to increase hepatitis B and C testing in China: a pilot randomized controlled trial| 2018
- 103
-
P1‐154: Integration of hepatitis B screening and prevention into ante‐natal care and delivery services in an urban cohort in Mozambique| 2018
- 104
-
P1‐158: Factors associated with hepatitis‐B virus infection among students in krachi senior high school in the Krachi West district of the Volta region| 2018
- 104
-
P1‐155: Prevalence and status of hepatitis B viral Infection among healthcare workers in a tertiary health institution in south western Nigeria| 2018
- 106
-
P1‐159: Huge expenditure prior to the diagnosis is a barrier in treatment of Hepatitis patients in low resource settings.| 2018
- 107
-
P1‐163: Assessing the diagnostic accuracy of viral hepatitis B and C health administrative diagnosis and billing codes using linked laboratory and administrative health databases in Ontario, Canada| 2018
- 107
-
P1‐161: Prevalence of hepatitis B virus in the Pa&Ka medical laboratory, Bamako, Mali| 2018
- 107
-
P1‐160: HBV and HCV test uptake and correlates among men who have sex with men in China: a nationwide cross‐sectional online survey| 2018
- 108
-
Innovative technologies for point‐of‐care testing of viral hepatitis in low‐resource and decentralized settingsDuchesne, L. / Lacombe, K. et al. | 2018
- 108
-
P1‐164: Hepatitis B during gestation: a cross‐sectional approach in the Western Brazilian Amazon| 2018
- 109
-
P1‐167: Hepatitis delta in Brazil| 2018
- 109
-
P1‐165: Hepatitis B core immunoglobulin G antibody (Anti‐HBc IgG) avidity index to differentiate acute from chronic hepatitis B virus (HBV) infection in cases with persistent anti‐HBc immunoglobulin M (Anti‐HBc IgM)| 2018
- 109
-
P1‐166: Prevalence of hepatitis B virus infection in a South African hospital‐based population born after the introduction of the hepatitis B vaccine in 1995| 2018
- 110
-
P1‐168: The prevalence of HBs Ag in peripheral blood of unvaccinated high school students| 2018
- 110
-
P1‐169: Analysis of site specific N‐glycosylation of serum haptoglobin beta in different liver diseases| 2018
- 111
-
P1‐171: Performance of point of care assays for hepatitis B and C viruses in chronic kidney disease patients| 2018
- 111
-
P1‐173: Prevalence and risk factors for hepatitis B infection in men in the penitentiary system in Paraná, Brazil| 2018
- 112
-
P1‐176: Linkage to care: the critical factor for Malaysia to reach hepatitis C elimination?| 2018
- 112
-
P1‐175: Chronic hepatitis B: MELD scores as an auxiliary mechanism in the classification of active liver disease in the Western Brazilian Amazon| 2018
- 113
-
P2‐002: Characterization of the HEV‐specific CD8 + T‐cell response in acute and chronic Hepatitis E virus infection| 2018
- 113
-
P1‐177: Getting to elimination: Lessons learned in developing scenarios for national hepatitis program scale up| 2018
- 114
-
P2‐003: Molecular diversity of HDV strains that spread in France: a study of 2224 clinical strains prospectively collected from 2001 to 2016| 2018
- 114
-
P2‐004: Molecular diversity of HBV and HDV amino‐acid sequences involved in HDV virion morphogenesis according to HBV and HDV genotypes: study of 1590 clinical strains| 2018
- 115
-
P2‐005: Hepatitis D virus infection in Canada: molecular epidemiology and clinical association| 2018
- 116
-
P2‐006: Evaluation of antigens for serologic detection of Hepatitis E virus| 2018
- 116
-
P2‐007: Failure of the CD8 + T Cell Response during viral Liver Infection critically depends on the Grade of Liver Damage| 2018
- 117
-
P2‐009: A systematic analysis of the hepatitis E virus host range across evolutionary diverse species| 2018
- 117
-
P2‐010: Molecular characterization of hepatitis D among hepatitis B and HIV co infected population attending antiretroviral clinic in Abuja Nigeria| 2018
- 118
-
P2‐011: Outcome of anti‐viral immunity in the liver is shaped by the level of antigen expressed in infected hepatocytes| 2018
- 118
-
Efficacy and safety results of patients with HCV genotype 2 or 3 infection treated with ombitasvir/paritaprevir/ritonavir and sofosbuvir with or without ribavirin (QUARTZ II‐III)Shafran, S. D. / Shaw, D. / Charafeddine, M. / Agarwal, K. / Foster, G. R. / Abunimeh, M. / Pilot‐Matias, T. / Pothacamury, R. K. / Fu, B. / Cohen, E. et al. | 2018
- 118
-
P2‐013: A bioactive peptide ameliorates diet‐induced nonalcoholic fatty liver in senescence accelerated mice prone 8 (SAMP8)‐genetic ageing model| 2018
- 119
-
P2‐019: The role of USP18 in macrophage polarization and interferon resistance in the liver inflammatory microenvironment| 2018
- 119
-
P2‐018: Mechanism of enhanced hepatic fibrosis by HCV/HIV co‐infection revealed by using co‐culture system consisting of primary macrophages, hepatic stellate cells and hepatocytes| 2018
- 120
-
P2‐021: Transforming growth factor‐beta1 gene polymorphism and its plasma level in Bangladeshi patients with chronic HCV infection| 2018
- 120
-
P2‐022: The epidemiological features of nonalcoholic fatty liver disease‐ a community‐based study in Taiwan| 2018
- 121
-
P2‐025: An overview of multidimensional approach of Unani medicine for fatty liver (Tashammul Kabid): review study (poster presentation)| 2018
- 121
-
P2‐026: Entropy of Mitochondrial DNA circulating in blood enables the accurate prediction of Hepatocellular carcinoma| 2018
- 121
-
P2‐023: PIVKA‐II and AFP quantification during the monitoring of HCV treatment| 2018
- 122
-
P2‐027: Enhanced virome analysis in acute liver failure patients with unknown etiology| 2018
- 123
-
P2‐028: Identification and characterisation of HLA‐A2 restricted CD8 + T cell immune hierarchy against full length hepatitis e virus (HEV) for chronic HEV T cell‐based therapy development| 2018
- 123
-
P2‐030: Immunity against Pre‐S1, Pre‐S2 and S antigens after immunization with a third generation hepatitis B vaccine| 2018
- 124
-
P2‐032: Derivation and validation of a novel dynamic model for predicting outcome in patients with hepatitis B virus related acute‐on‐chronic liver failure| 2018
- 124
-
P2‐031: PIB, a simple score to select sorafenib treatment candidates for viral‐associated hepatocellular carcinoma in resource‐limited settings| 2018
- 125
-
P2‐033: Eukaryotic virome profile interactions in liver transplant recipients infected by HBV| 2018
- 126
-
P2‐035: Ursodeoxycholic acid is associated with an improved liver transplantation‐free survival in primary biliary cholangitis| 2018
- 126
-
Nonstructural protein 5A resistance profile in patients with chronic hepatitis C treated with ledipasvir‐containing regimens without sofosbuvirKitrinos, K. M. / Corsa, A. C. / Worth, A. / Hedskog, C. / Brainard, D. M. / Miller, M. D. / Mo, H. et al. | 2018
- 126
-
P2‐036: Time trends in liver transplantation for primary biliary cholangitis in europe over the past three decades| 2018
- 127
-
P2‐038: Prevalence of baseline NS5A inhibitor resistance‐associated variants in Brazilian patients infected with genotypes 1 and 3| 2018
- 128
-
P2‐039: Time to diagnosis of hepatocellular carcinoma (HCC) and pretreatment risk factors in successfully treated, with interferon/ribavirin, chronic HCV patients| 2018
- 128
-
P2‐040: Thirteen years of acute liver failure investigation – retrospective analysis of challenges in viral hepatitis prevention and control| 2018
- 129
-
P2‐041: Serum levels of novel adipokines in patients with hepatocellular carcinoma| 2018
- 129
-
P2‐042: The role of the parvovirus b19 infection in cases of liver failure: could B19V be an agent of acute liver failure and acute‐on‐chronic liver failure?| 2018
- 130
-
P2‐044: Impact of integrating hepatitis C education and automated electronic medical record hepatitis C testing orders at a federally qualified health center| 2018
- 130
-
P2‐045: Mapping progress towards Australia’s national hepatitis C strategy targets| 2018
- 131
-
P2‐046: Estimating the number of people who inject drugs and the coverage of harm reduction services in Canada| 2018
- 131
-
P2‐048: Very late diagnosis of chronic hepatitis C infection| 2018
- 132
-
P2‐050: Evaluating hepatitis C core antigen as a screening test in populations at high risk of hepatitis C virus (HCV) infection| 2018
- 132
-
P2‐049: Relationship of hydromorphone controlled release prescribing and hepatitis C incidence in Ontario, Canada| 2018
- 133
-
P2‐053: The effect of hepatitis C screening on substance‐use behaviors in patients engaged in opioid substitution therapy| 2018
- 133
-
P2‐051: Can we afford not to screen for and treat HCV infection in Canada| 2018
- 134
-
Resistance characterization of ledipasvir and velpatasvir in hepatitis C virus genotype 4Camus, G. / Han, B. / Asselah, T. / Hsieh, D. / Dvory‐Sobol, H. / Lu, J. / Svarovskaia, E. / Martin, R. / Parhy, B. / Miller, M. D. et al. | 2018
- 134
-
P2‐054: Usefulness of saliva samples for HCV RNA detection: important tool to increase diagnosis access in low resource areas| 2018
- 134
-
P2‐055: Screening for hepatitis C in Ontario, Canada: exploring antibody positivity in the federal and provincial correctional systems| 2018
- 135
-
P2‐056: Syndemic characterization of HCV, HBV, and HIV co‐infections in a large population based cohort study| 2018
- 136
-
P2‐057: The burden of viral hepatitis C in key subgroups in Belgium: targets for micro‐elimination| 2018
- 136
-
P2‐059: Reversal proportion of Hepatitis C as underlying cause of death by age and gender in Brazil, 2000–2015| 2018
- 137
-
P2‐060: Hepatitis C virus reinfection after successful treatment with all‐oral, direct‐acting antiviral therapy in a large population‐based cohort including people who inject drugs| 2018
- 138
-
P2‐061: Validation of a low cost, point of care screening device for HCV antibody detection in low resource peri‐urban settings of Karachi, Pakistan| 2018
- 138
-
P2‐062: HCV elimination strategy in Vietnam: willingness to pay for treatment among patients receiving ART or MMT| 2018
- 139
-
P2‐064: Viral hepatitis accounts for nearly half of the hospitalization burden among cirrhosis patients hospitalized in the United States| 2018
- 139
-
P2‐063: Hepatitis C infection in the Middle East and North Africa: systematic overview, quality assessment, and evidence gap mapping| 2018
- 140
-
P2‐065: Estimates and projection of disease burden and investment case for hepatitis C in Viet Nam| 2018
- 141
-
P2‐066: Hepatitis C virus and human immunodeficiency virus infections and associated risk factors among pregnant women attending antenatal care clinic in West Ethiopia| 2018
- 142
-
P2‐067: Emergence among men in Quebec, Canada of a hepatitis C virus genotype 4D lineage circulating in European HIV‐infected men| 2018
- 142
-
P2‐068: Evaluation of a clinical decision support program for ambulatory screening of hepatitis‐C in a large national EHR platform| 2018
- 143
-
P2‐069: Preliminary cure rates from the national HCV pilot program in Vietnam| 2018
- 143
-
P2‐070: Nosocomal transmission of hepatitis C viruses (HCV) in a hemodialysis unit: molecular evidence| 2018
- 144
-
P2‐073: Determination of hepatitis C virus RNA stability in different storage conditions| 2018
- 144
-
Sustained virological response to ombitasvir/paritaprevir/ritonavir and dasabuvir treatment for hepatitis C: Real‐world data from a large healthcare providerWeil, C. / Mehta, D. / Koren, G. / Pinsky, B. / Samp, J. C. / Chodick, G. / Shalev, V. et al. | 2018
- 144
-
P2‐071: Towards HCV micro‐elimination: why HCV is not like HIV| 2018
- 145
-
P2‐076: Performance evaluation of VIKIA® ANTI‐HCV, rapid test for the qualitative detection of antibodies anti‐HCV in European and non‐European populations| 2018
- 145
-
P2‐074: Evaluation of the diagnostic performance of five rapid diagnostic tests for Hepatitis C virus antibody detection in India| 2018
- 146
-
P2‐078: Chronic hepatitis C virus: challenge from testing to treatment| 2018
- 146
-
P2‐077: Hepatitis C among MSM suggesting sexual transmission and importation of a HCV strain previously unreported in Brazil| 2018
- 147
-
P2‐080: Innovative model for identifying and treating HCV at substance use treatment providers| 2018
- 147
-
P2‐079: Hepatitis C virus epidemiology in Iran: systematic review, meta‐analyses and meta‐regression| 2018
- 148
-
P2‐081: National hepatitis C campaign in Argentina: raising awareness using printed information and offering rapid tests| 2018
- 149
-
P2‐083: A high demand for hepatitis C education among healthcare providers in British Columbia| 2018
- 149
-
P2‐085: Distribution, diversity, and patterns of hepatitis C virus genotypes in the Middle East and North Africa| 2018
- 149
-
P2‐084: Predictive markers for hepatitis C virus infection among Brazilian inmates| 2018
- 150
-
P2‐086: Same‐sex behaviour and its association with HCV acquisition in a cohort of people who inject drugs| 2018
- 150
-
P2‐087: Epidemiological profile of Hepatitis C in pregnant women: a population study in the Western Brazilian Amazon| 2018
- 151
-
P2‐089: Heterogenous distribution of HCV genotypes and outcome of treatment| 2018
- 151
-
P2‐088: A two‐year retrospective study of hepatitis C virus genotypes distribution in hepatocellular carcinoma patients| 2018
- 152
-
Trends in hepatitis C‐related mortality in SwitzerlandKeiser, O. / Giudici, F. / Müllhaupt, B. / Junker, C. / Dufour, J. ‐F. / Moradpour, D. / Bruggmann, P. / Terziroli, B. / Semela, D. / Brezzi, M. et al. | 2018
- 152
-
P2‐090: Viral hepatitis surveillance by sentinel units in Argentina: analysis after 11 years| 2018
- 153
-
P2‐091: Scale up of hepatitis C virus treatment in the era of expanded access to all‐oral direct‐acting antivirals (DAAs): a 9‐year Greek cohort study| 2018
- 153
-
P2‐092: The hepatitis prevention, control, and elimination program in Mongolia: a model for eliminating viral hepatitis in low and middle income countries with high burden of hepatitis related morbidity and mortality| 2018
- 154
-
P2‐093: Using rapid point‐of‐care HCV testing to engage marginalized inner‐city populations| 2018
- 154
-
P2‐094: Lack of awareness of hepatitis B and C diagnoses in a population‐based survey of adults living in the United States (US): a National Health and Nutrition Examination Survey (NHANES) Study| 2018
- 155
-
P2‐095: The establishment of hepatitis B care and treatment clinics in the United Republic of Tanzania: a demonstration project following WHO guidelines| 2018
- 156
-
P2‐096: HCV: Bringing care to patients in rural and remote settings| 2018
- 156
-
P2‐097: Linkage and care of people living with chronic hepatitis B infection accessing monitoring and evaluation services at treatment and care cascade in limited resource‐settings| 2018
- 157
-
P2‐098: Elimination of hepatitis C in Brazil is cost‐saving| 2018
- 157
-
P2‐099: A tale of two provinces: Comparison of the successes and challenges of structured, stepwise development in two Canadian provincial research and evaluation imbedded HCV elimination strategies| 2018
- 158
-
P2‐102: A systematic decision tool to support the selection of innovative financing mechanisms for treatment access programs in resource‐limited settings utilizing Hepatitis C in Mongolia as a case study| 2018
- 158
-
P2‐101: Implementation and impact of clinical decision support (CDS) tool to increase hepatitis C virus (HCV) screening among baby boomers in a large urban health system| 2018
- 159
-
P2‐103: Treatment of hepatitis C genotypes 1 to 5 in Sub‐Saharan Africa using direct‐acting antivirals| 2018
- 160
-
P2‐104: Analysis of the sero‐epidemiology and clinical manifestations of hepatitis E virus in South America| 2018
- 160
-
P2‐105: Spectrum of hepatitis B awareness among healthcare workers across Africa| 2018
- 161
-
P2‐107: Undergraduate nursing students’ hepatitis C (HCV) knowledge, attitudes and practices| 2018
- 161
-
P2‐106: Gilead sciences’ support of global efforts toward elimination of hepatitis C virus| 2018
- 161
-
Prevalence of hepatitis C infection and its associated factors in healthy adults without identifiable route of transmissionWong, N. S. / Lee, C. K. / Ng, S. C. / Wong, H. K. / Chan, D. P. C. / Lee, S. S. et al. | 2018
- 162
-
P2‐109: Evaluation of birth cohort hepatitis C screening program in an academic emergency department| 2018
- 162
-
P2‐110: Limited HCV awareness and hepatitis C virus stigma are common in a medium sized Canadian province before implementation of an elimination strategy but 2 years after DAA implementation| 2018
- 163
-
P2‐112: Values, preferences, and acceptability of hepatitis C testing and treatment in the homeless and vulnerably housed: a scoping review| 2018
- 163
-
P2‐111: Point‐of‐care tests for hepatitis B and C infection are associated with a higher linkage to care in an Asian migrant population| 2018
- 164
-
P2‐113: HCV testing and linkage to care: expanding access to HCV care through electronic health engagement| 2018
- 164
-
P2‐114: Gaps in care before introduction of a coordinated elimination strategy: a Canadian provincial baseline| 2018
- 165
-
P2‐115: Mental health, risk behaviors and substance use profiling of patients infected or at‐risk of acquiring hepatitis C seen in community and hospital care settings| 2018
- 165
-
P2‐118: Improving hepatitis screening and linkage‐to‐care rates using an interactive mobile messaging platform: pilot project in Mongolia, a country that has the highest burden of viral hepatitis and the lowest population density in the world| 2018
- 166
-
P2‐119: Evaluation of hepatitis C screening strategies in different community settings in a Canadian metropolitan area| 2018
- 167
-
P2‐121: Implementing a hepatitic C care and treatment outreach program in an urban setting: lessons learned| 2018
- 167
-
P2‐122: Implementation of the first french‐speaking ECHO hepatitis C program in a large tertiary ‐Quaternary Care University Hospital: participants’ satisfaction, knowledge and self‐confidence after year‐1| 2018
- 168
-
P2‐123: Successes and challenges of integrating HCV testing and linkage at an urban syringe exchange program| 2018
- 169
-
P2‐125: Reiki: antiviral therapy?| 2018
- 169
-
P2‐124: Hepatitis B knowledge, attitudes and beliefs in Arabic and Assyrian communities in Sydney, Australia: results of a community consultation| 2018
- 170
-
P2‐127: Integrating primary and secondary care to optimise hepatitis C treatment: development and evaluation of a Multidisciplinary Educational ‘Masterclass’ Series| 2018
- 170
-
P2‐126: Changes in characteristics of HCV infected patients treated in Poland between 2015 and 2017 – EpiTer‐2 study| 2018
- 171
-
Daily cannabis and reduced risk of steatosis in human immunodeficiency virus and hepatitis C virus‐co‐infected patients (ANRS CO13‐HEPAVIH)Nordmann, S. / Vilotitch, A. / Roux, P. / Esterle, L. / Spire, B. / Marcellin, F. / Salmon‐Ceron, D. / Dabis, F. / Chas, J. / Rey, D. et al. | 2018
- 171
-
P2‐128: Viral hepatitis: healthcare services organization, access and integrality| 2018
- 171
-
P2‐129: Seed the change: patient advocacy plugs the gaps in linkage to care. A case study of personal generic direct acting antivirals (DAA’s) importation and practivism in Aotearoa/New Zealand; and how this is, and could be, affected by international law| 2018
- 172
-
P2‐131: Health evaluation in the response to viral hepatitis in Brazil| 2018
- 172
-
P2‐132: Implementation of a hepatitis C elimination plan with a view on access expansion and integrality of viral hepatitis care| 2018
- 173
-
P2‐133: Development of HepFriend: a community hepatitis C peer support model| 2018
- 173
-
P2‐134: Strengthening integrated laboratory capacity and surveillance programs to improve strategic information to eliminate viral hepatitis in Mongolia| 2018
- 174
-
P2‐137: A large hepatitis a outbreak in Rio de Janeiro reinforces the need for vaccination of risk groups| 2018
- 175
-
P2‐139: Long‐term immunity to hepatitis B among Brazilian Amerindians who completed 3‐dose hepatitis B vaccination| 2018
- 175
-
P2‐138: Harm reduction and viral hepatitis C in European prisons: inadequate prevention measures in 25 European countries| 2018
- 176
-
P2‐140: Hepatitis serology among human immunodeficiency virus‐positive patients in Istanbul, Turkey| 2018
- 176
-
P2‐142: Evaluation of knowledge towards hepatitis B among secondary school students in Bobo‐Dioulasso, Burkina Faso| 2018
- 177
-
P2‐146: Some plants with antiviral properties in Benin and West Africa| 2018
- 177
-
P2‐143: Attitude and Vaccination status of health care workers against hepatitis B infection in a teaching hospital, Ethiopia: institution based cross sectional study| 2018
- 178
-
P2‐148: Immunogenicity and safety of 60 μg hepatitis B vaccine with rapid immunization compared with traditional 20 μg regimens in adults aged 25–55 in China| 2018
- 179
-
P2‐150: Moving towards WHO hepatitis elimination targets: lessons learned from World Hepatitis Day Canada| 2018
- 179
-
P2‐149: Association between CD4 count level and immune response to hepatitis B vaccination: a prospective study of HIV‐positive adults in China| 2018
- 180
-
Bacterial translocation and clinical progression of HCV‐related cirrhosis in HIV‐infected patientsMerchante, N. / Aldámiz‐Echevarría, T. / García‐Álvarez, M. / Rivero‐Juárez, A. / Macías, J. / Miralles, P. / Jiménez‐Sousa, M. A. / Mancebo, M. / Pérez‐Latorre, L. / Pineda‐Tenor, D. et al. | 2018
- 180
-
P2‐151: Perceived adequacy of opiate agonist therapy dosage is associated with risk of hepatitis C virus infection among people who inject drugs: examining the role of flexible, patient‐centered approaches in HCV prevention| 2018
- 181
-
P2‐153: Harm reduction coverage and risk of HCV infection: a comparison of HCV‐Naïve and previously‐infected people who inject drugs| 2018
- 181
-
P2‐152: Barriers and facilitators to hepatitis B immunization among sex workers: implications for integrated HIV, STI, and viral hepatitis services| 2018
- 182
-
P2‐154: Efficacy of hepatitis B virus vaccination in genotype 4 chronic hepatitis C patients achieved sustained virologic response with direct acting antivirals| 2018
- 183
-
P2‐155: Regional differences in the prevalence of hepatitis B virus (HBV) infection and disease awareness among pregnant women in a highly‐endemic SSA country| 2018
- 183
-
P2‐158: Attenuated listeria monocytogenes as a promising preventive‐ and treatment vaccine candidate in the settings of hepatobiliary cancer| 2018
- 184
-
P2‐159: Prevention is better than cure| 2018
- 185
-
P2‐162: Hepatitis A virus molecular surveillance in Argentina after 13 years of universal vaccination| 2018
- 185
-
P2‐161: Hepatitis B infection in Argentina five years after implementation of universal vaccination| 2018
- 186
-
P2‐163: Street shot: preventing hepatitis through art| 2018
- 186
-
P2‐164: Immunization status of cohort of children vaccinated against hepatitis B virus in Ekiti state ten years after incorporation into National Program on Immunization| 2018
- 187
-
Rare clinically significant hepatic events and hepatitis B reactivation occur more frequently following rather than during direct‐acting antiviral therapy for chronic hepatitis C: Data from a national US cohortSerper, M. / Forde, K. A. / Kaplan, D. E. et al. | 2018
- 187
-
P2‐166: Determinants of five pillars of sanitation behavior against the occurrence of hepatitis in Indonesia| 2018
- 187
-
P2‐165: Strategies and innovations of the prevention campaign of the hepatitis prevention, control, and elimination program in Mongolia: analytical and data‐driven approach for creative utilization of social media| 2018
- 188
-
P2‐167: Sixteen years after the implementation of compulsory hepatitis B vaccination in a hepatitis delta endemic area in Greece: comparison between two population‐based serosurveys| 2018
- 188
-
P2‐117: Overcoming barriers to achieve HCV elimination in Greece| 2018
- 190
-
LBO‐02: Utility of a new HBV RNA assay in HBeAg positive and negative CHB and following HBsAg seroclearance in patients treated with ARC‐520, an RNAi drug targeting cccDNA derived HBV mRNA| 2018
- 190
-
LBO‐01: First in human, single ascending dose clinical trial of AIC649 in patients with chronic hepatitis B| 2018
- 191
-
LBO‐03: Development of a 3D spheroid system of primary human hepatocytes that supports efficient HBV infection| 2018
- 192
-
LBO‐04: High incidence of hepatitis C virus (re‐)infections among PrEP users in the Netherlands: implications for prevention, monitoring and treatment| 2018
- 192
-
LBO‐05: Integrating HCV and HIV services improves HCV testing and awareness among people who inject drugs in India: findings from a cluster randomized trial| 2018
- 193
-
LBO‐06: Retreatment with Sofosbuvir/Velpatasvir/Voxilaprevir for 12 weeks is safe and effective for patients who have previously received Sofosbuvir/Velpatasvir or Sofosbuvir/Velpatasvir/Voxilaprevir| 2018
- 194
-
LBP‐001: Epidemiology and risk factors associated with liver cancer in South Africa| 2018
- 194
-
LBP‐002: Novel ImmTAV molecules for the treatment of HBV| 2018
- 195
-
LBP‐003: Management of viral hepatitis B and C in Guinea: first results| 2018
- 195
-
LBP‐004: Serum ALT flares during pregnancy in prospectively monitored women with chronic hepatitis B infection| 2018
- 196
-
LBP‐005: Efficacy and safety of Sofosbuvir/Velpatasvir for the treatment of treatment‐naïve, non‐cirrhotic patients with chronic hepatitis C genotype 3 infection: integrated analysis of three phase 3 clinical trials| 2018
- 197
-
LBP‐007: Real‐world data on safety and effectiveness of glecaprevir/pibrentasvir for the treatment of patients with chronic hepatitis C virus infection: updated data from the German Hepatitis C‐Registry| 2018
- 197
-
LBP‐006: Sofosbuvir‐ Daclatasvir: Effectiveness among cirrhotic and non‐cirrhotic genotype 1 to 4 HCV patients, in real world settings| 2018
- 198
-
Eighteen‐month lamivudine prophylaxis on preventing occult hepatitis B virus infection reactivation in patients with haematological malignancies receiving immunosuppression therapyMarrone, A. / Capoluongo, N. / D'Amore, C. / Pisaturo, M. / Esposito, M. / Guastafierro, S. / Siniscalchi, I. / Macera, M. / Boemio, A. / Onorato, L. et al. | 2018
- 198
-
LBP‐008: SD1000: 96.4% SVR12 in 1237 patients with hepatitis C genotypes 1, 2, 3, 4 using co‐formulated sofosbuvir/daclatasvir tablets manufactured in Iran – a multicenter phase 3 clinical trial including HIV co‐infected, transplant, and hemodialysis patients| 2018
- 199
-
LBP‐009: The association between diabetes mellitus and hepatitis C chronic infection: frequency and mutual interaction| 2018
- 200
-
LBP‐010: Factors affecting the outcome of hepatitis in pregnancy. Is Hepatitis E a culprit?| 2018
- 200
-
LBP‐011: “Sickle cell intrahepatic cholestasis: Molecular Adsorbent Recirculating System (MARS) as therapy and a bridge to liver transplant”| 2018
- 201
-
LBP‐012: Viral hepatitis is not the main cause of acute liver failute leading to liver transplantation in Brazil| 2018
- 201
-
LBP‐013: Prediction of serious liver disease in ALT‐normal, HBeAg‐negative chronic hepatitis B virus (HBV) infection of genotype C| 2018
- 202
-
LBP‐015: Seroprevalence of hepatitis B and C in blood donors at the transfusion center, Coyah Prefectural Hospital| 2018
- 202
-
LBP‐014: “Village free hepatitis”: Psycho‐socio‐medical approach in a low‐income Country| 2018
- 203
-
LBP‐016: Lost to follow‐up among Ledipasvir/sofosbuvir treated patients in Canada: The BC Hepatitis Testers Cohort| 2018
- 203
-
LBP‐017: Dried blood spot samples as alternative specimen for hepatitis C diagnosis| 2018
- 204
-
LBP‐019: Validation of home‐sampled dried blood spots for HIV and HCV‐RNA load measurements| 2018
- 204
-
LBP‐018: Epidemiological analysis of hepatitis C in Pakistan and other Countries: a current update| 2018
- 205
-
Treatment of hepatitis C with 8 weeks of ledipasvir/sofosbuvir: Highly effective in a predominantly black male patient populationTang, L. / Parker, A. / Flores, Y. / Dellario, M. / Dickson, C. / Amoroso, A. / Kottilil, S. / Wilson, E. et al. | 2018
- 205
-
LBP‐021: Field friendly hepatitis diagnostic| 2018
- 205
-
LBP‐020: Working towards eliminating HCV among men who have sex with men in Amsterdam using an innovative multilevel approach: The NoMoreC project| 2018
- 206
-
LBP‐022: Peers4Wellness: Indigenous, Peer‐Led, Wellness Support for HCV and/or HIV Care| 2018
- 206
-
LBP‐023: Case management and capacity building to enhance hepatitis C treatment‐uptake at community health centers in a large urban setting| 2018
- 207
-
LBP‐024: The prevalence of chronic untreated hepatitis C virus infection and associated risk factors within a prison population: a cross sectional study| 2018
- 207
-
LBP‐025: America's $10 billion overspend on Sofosubvir‐based hepatitis C treatment resulting from unmerited patents| 2018
- 208
-
LBP‐026: History of HCV transmission in high‐risk populations in Vietnam| 2018
- 208
-
LBP‐027: Outreach approach on delivering tailored information about hepatitis B&C to injecting drug users (IDUs) in manner that is understood and establish active monitoring mechanism where service needs of IDUs is identified and linked to required care| 2018
- 209
-
LBP‐028: Ethical considerations in the development of a comprehensive hepatitis B testing programme| 2018
- 209
-
Genotype 4 hepatitis E virus is a cause of chronic hepatitis in renal transplant recipients in Hong KongSridhar, S. / Chan, J. F. W. / Yap, D. Y. H. / Teng, J. L. L. / Huang, C. / Yip, C. C. Y. / Hung, I. F. N. / Tang, S. C. W. / Lau, S. K. P. / Woo, P. C. Y. et al. | 2018
- 209
-
LBP‐029: In Bangladesh's trucking industry: Human immunodeficiency virus, hepatitis B, C and D prevalence and risk factors| 2018
- 211
-
Author Index| 2018
- 214
-
Successful treatment of chronic hepatitis C with ground ledipasvir/sofosbuvir in a patient with Crohn's disease and short bowel syndromevon Felden, J. / Scheurich, C. / Yamamura, J. / Brainard, D. M. / Mogalian, E. / Lohse, A. W. / Schulze zur Wiesch, J. et al. | 2018
- 220
-
Understanding and addressing hepatitis C reinfection in the oral direct‐acting antiviral eraFalade‐Nwulia, O. / Sulkowski, M. S. / Merkow, A. / Latkin, C. / Mehta, S. H. et al. | 2018
- 228
-
Impact of ledipasvir/sofosbuvir on the work productivity of genotype 1 chronic hepatitis C patients in AsiaYounossi, Z. M. / Chan, H. L. Y. / Dan, Y. Y. / Lee, M. H. / Lim, Y. ‐S. / Kruger, E. / Tan, S. C. et al. | 2018
- 236
-
Community‐based screening of hepatitis C with a one‐step RNA detection algorithm from dried‐blood spots: Analysis of key populations in Barcelona, SpainSaludes, V. / Folch, C. / Morales‐Carmona, A. / Ferrer, L. / Fernàndez‐López, L. / Muñoz, R. / Jiménez, M. / Loureiro, E. / Fernández‐Dávila, P. / Bascuñana, E. et al. | 2018
- 245
-
Enhanced natural killer cell activity is found in exposed uninfected recipients of hepatitis C‐contaminated bloodOw, M. M. / Hegazy, D. / Warshow, U. M. / Cramp, M. E. et al. | 2018
- 254
-
Lower levels of dehydroepiandrosterone sulfate are associated with more advanced liver fibrosis in chronic hepatitis Cde Araujo Neto, J. M. / Coelho, H. S. M. / Chindamo, M. C. / Rezende, G. F. M. / Nunes Pannain, V. L. / Bottino, A. M. C. F. / Bruzzi Porto, L. F. / Luiz, R. R. / Villela‐Nogueira, C. A. / Perez, R. M. et al. | 2018
- 262
-
In vivo analysis at the cellular level reveals similar steatosis induction in both hepatitis C virus genotype 1 and 3 infectionsCampana, B. / Calabrese, D. / Matter, M. S. / Terracciano, L. M. / Wieland, S. F. / Heim, M. H. et al. | 2018
- 272
-
Risk of diabetes in viral hepatitis B or C patients compared to that in noninfected individuals in Korea, 2002‐2013: A population‐based cohort studyChoi, H. Y. / Kim, Y. / Cho, H. / Kim, B. H. / Ki, M. et al. | 2018
- 281
-
Prevalence and natural course of occult hepatitis B virus infection in residents of 2 communities of Wuwei City, Gansu Province, ChinaWen, X. / Su, H. / Wang, Y. / Pu, Z. / Gao, J. / Ji, Z. / Yuan, X. / Li, X. / Zhang, W. / Zhang, L. et al. | 2018
- 289
-
Alpha‐enolase regulates hepatitis B virus replication through suppression of the interferon signalling pathwayXiang‐Chun, D. / Xiao‐qing, Y. / Ting‐Ting, Y. / Zhen‐Hui, L. / Xiao‐Yan, L. / Xia, L. / Yan‐Chao, H. / Yi‐Xuan, Y. / Li‐Na, M. et al. | 2018
- 296
-
Interpretation of liver stiffness measurement‐based approach for the monitoring of hepatitis B patients with antiviral therapy: A 2‐year prospective studyLiang, X. / Xie, Q. / Tan, D. / Ning, Q. / Niu, J. / Bai, X. / Chen, S. / Cheng, J. / Yu, Y. / Wang, H. et al. | 2018
- 306
-
Role of Functional IFNL4,IFNLR1,IFNA,IFNAR2 Polymorphisms in Hepatitis B virus‐related liver disease in Han Chinese populationMa, N. / Zhang, X. / Yang, L. / Zhou, J. / Liu, W. / Gao, X. / Yu, F. / Zheng, W. / Ding, S. / Gao, P. et al. | 2018
- 314
-
Impaired patient‐reported outcomes persist in HIV‐HCV co‐infected patients and in cirrhotic patients despite HCV clearanceMarcellin, F. / Morlat, P. / Wittkop, L. / Salmon‐Ceron, D. / Carrieri, M. P. et al. | 2018
- 320
-
The benefits of hepatitis C virus cure: Every rose has thornsSalmon, D. / Mondelli, M. U. / Maticic, M. / Arends, J. E. / The ESCMID Study Group for Viral Hepatitis et al. | 2018
- 329
-
Disappearance of perihepatic lymph node enlargement after hepatitis C viral eradication with direct‐acting antiviralsHikita, H. / Sato, Masaya / Endo, Momoe / Sato, Mamiko / Soroida, Y. / Kobayashi, T. / Gotoh, H. / Iwai, T. / Nakagomi, R. / Tateishi, R. et al. | 2018
- 335
-
Elastogram quality assessment score in vibration‐controlled transient elastography: Diagnostic performance compared to digital morphometric analysis of liver biopsy in chronic hepatitis CMendes, L. C. / Ferreira, P. A. / Miotto, N. / Zanaga, L. / Gonçales, E. S. L. / Pedro, M. N. / Lazarini, M. S. / Júnior, F. L. G. / Stucchi, R. S. B. / Vigani, A. G. et al. | 2018
- 344
-
Intrapatient viral diversity and treatment outcome in patients with genotype 3a hepatitis C virus infection on sofosbuvir‐containing regimensBhardwaj, N. / Ragonnet‐Cronin, M. / Murrell, B. / Chodavarapu, K. / Martin, R. / Chang, S. / Miller, M. D. / Feld, J. J. / Sulkowski, M. / Mangia, A. et al. | 2018
- 354
-
Quality of life in adolescents with hepatitis C treated with sofosbuvir and ribavirinYounossi, Z. M. / Stepanova, M. / Schwarz, K. B. / Wirth, S. / Rosenthal, P. / Gonzalez‐Peralta, R. / Murray, K. / Henry, L. / Hunt, S. et al. | 2018
- 363
-
Trends in the total numbers of HBV and HCV carriers in Japan from 2000 to 2011Tanaka, J. / Akita, T. / Ohisa, M. / Sakamune, K. / Ko, K. / Uchida, S. / Satake, M. et al. | 2018
- 373
-
Changes and analysis of anti‐HBs titres after primary immunization in 1‐ to 16‐year‐old Chinese children: A hospital‐based studyYue, X. / Ge, C. / Zhuge, S. / He, H. / Yang, H. / Xu, H. / Huang, A. / Zhao, Y. et al. | 2018
- 381
-
Unconventional T cells in chronic hepatitis B patients on long‐term suppressive therapy with tenofovir followed by a Peg‐IFN add‐on strategy: A randomized studyCannizzo, E. S. / Tincati, C. / Binda, F. / Ronzi, P. / Cazzaniga, F. A. / Antinori, S. / d'Arminio Monforte, A. / Marchetti, G. / Milazzo, L. et al. | 2018
- 391
-
LncRNA expression profiles in HBV‐transformed human hepatocellular carcinoma cells treated with a novel inhibitor of human La proteinPan, J. / Tong, S. / Tang, J. et al. | 2018
- 401
-
Distribution of ABO/Rh blood groups and their association with hepatitis B virus infection in 3.8 million Chinese adults: A population‐based cross‐sectional studyLiu, J. / Zhang, S. / Liu, M. / Wang, Q. / Shen, H. / Zhang, Y. et al. | 2018
- 412
-
A direct role for hepatitis B virus X protein in inducing mitochondrial membrane permeabilizationLee, H‐R. / Cho, Y. Y. / Lee, G. Y. / You, D‐g. / Yoo, Y. D. / Kim, Y. J. et al. | 2018
- 421
-
Great and rapid HBsAg decline in patients with on‐treatment hepatitis flare in early phase of potent antiviral therapyJeng, W.‐J. / Chen, Y.‐C. / Liaw, Y.‐F. et al. | 2018
- 429
-
Safety and efficacy of telbivudine in late pregnancy to prevent mother‐to‐child transmission of hepatitis B virus: A multicenter prospective cohort studyHu, Y. / Xu, C. / Xu, B. / Hu, L. / Liu, Q. / Chen, J. / Liu, J. / Liu, L. / Yang, J. / Chen, T. et al. | 2018
- 438
-
Internal funding required to improve HIV careBrownstein, H. / Higgs, P. et al. | 2018
- 442
-
Host genetic factors associated with hepatocellular carcinoma in patients with hepatitis c virus infection: a systematic reviewWalker, A. J. / Peacock, C. J. / Pedergnana, V. / Irving, W. L. et al. | 2018
- 457
-
Efficacy and safety of 12 weeks of elbasvir ± grazoprevir ± ribavirin in participants with hepatitis c virus genotype 2, 4, 5 or 6 infection: the c‐scape studyBrown, A. / Hézode, C. / Zuckerman, E. / Foster, G. R. / Zekry, A. / Roberts, S. K. / Lahser, F. / Durkan, C. / Badshah, C. / Zhang, B. et al. | 2018
- 465
-
Ifn‐free therapy is associated with restoration of type i ifn response in hiv‐1 patients with acute hcv infection who achieve svrCarlton‐Smith, C. / Holmes, J. A. / Naggie, S. / Lidofsky, A. / Lauer, G. M. / Kim, A. Y. / Chung, R. T. et al. | 2018
- 473
-
Trends in hepatocellular carcinoma incidence and survival among people with hepatitis c: an international studyAlavi, M. / Janjua, N. Z. / Chong, M. / Grebely, J. / Aspinall, E. J. / Innes, H. / Valerio, H. / Hajarizadeh, B. / Hayes, P. C. / Krajden, M. et al. | 2018
- 482
-
Establishing the cascade of care for hepatitis c in england—benchmarking to monitor impact of direct acting antiviralsSimmons, R. / Ireland, G. / Irving, W. / Hickman, M. / Sabin, C. / Ijaz, S. / Ramsay, M. / Lattimore, S. / Mandal, S. et al. | 2018
- 491
-
The antiviral role of zinc and metallothioneins in hepatitis c infectionRead, S. A. / Parnell, G. / Booth, D. / Douglas, M. W. / George, J. / Ahlenstiel, G. et al. | 2018
- 502
-
Estimating chronic hepatitis c prognosis using transient elastography‐based liver stiffness: a systematic review and meta‐analysisErman, A. / Sathya, A. / Nam, A. / Bielecki, J. M. / Feld, J. J. / Thein, H‐H. / Wong, W. W. L. / Grootendorst, P. / Krahn, M. D. et al. | 2018
- 514
-
Assessing uncertainty in the burden of hepatitis c virus: comparison of estimated disease burden and treatment costs in the ukGubay, F. / Staunton, R. / Metzig, C. / Abubakar, I. / White, P. J. et al. | 2018
- 524
-
Prevalence of mixed genotype hepatitis c virus infections in the uk as determined by genotype‐specific pcr and deep sequencingMcNaughton, A. L. / Sreenu, V. B. / Wilkie, G. / Gunson, R. / Templeton, K. / Leitch, E. C. M. et al. | 2018
- 535
-
The presence of multiple ns5a rass is associated with the outcome of sofosbuvir and ledipasvir therapy in ns5a inhibitor‐naïve patients with chronic hcv genotype 1b infection in a real‐world cohortKozuka, R. / Hai, H. / Motoyama, H. / Hagihara, A. / Fujii, H. / Uchida‐Kobayashi, S. / Morikawa, H. / Enomoto, M. / Murakami, Y. / Kawada, N. et al. | 2018
- 543
-
Temporal trend and risk determinants of hepatocellular carcinoma in chronic hepatitis b patients on entecavir or tenofovirHsu, Yao‐Chun / Ho, Hsiu‐J. / Lee, Teng‐Yu / Huang, Yen‐Tsung / Wu, Ming‐Shiang / Lin, Jaw‐Town / Wu, Chun‐Ying / El‐Serag, Hashem B. et al. | 2018
- 552
-
Delayed viral suppression during antiviral therapy is associated with increased hepatocellular carcinoma rates in hbeag‐positive high viral load chronic hepatitis bNam, J. Y. / Chang, Y. / Cho, H. / Kang, S. H. / Cho, Y. Y. / Cho, E. J. / Lee, J.‐H. / Yu, S. J. / Yoon, J.‐H. / Kim, Y. J. et al. | 2018
- 561
-
Knowledge regarding hepatitis b mother‐to‐child transmission among healthcare workers in south chinaChen, Y. / Xie, C. / Zhang, Y. / Li, Y. / Ehrhardt, S. / Thio, C. L. / Nelson, K. E. / Lin, C.‐S. et al. | 2018
- 571
-
Incidence and prevalence of hepatitis b in patients with diabetes mellitus in the uk: a population‐based cohort study using the uk clinical practice research datalinkFerreira, G. L. C. / Marano, C. / De Moerlooze, L. / Guignard, A. / Feng, Y. / El Hahi, Y. / van Staa, T. et al. | 2018
- 581
-
Comparative evaluation of gpr versus apri and fib‐4 in predicting different levels of liver fibrosis of chronic hepatitis bLiu, D.‐P. / Lu, W. / Zhang, Z.‐Q. / Wang, Y.‐B. / Ding, R.‐R. / Zhou, X.‐L. / Huang, D. / Li, X.‐F. et al. | 2018
- 590
-
The incidence and predictors of hbv relapse after cessation of tenofovir therapy in chronic hepatitis b patientsChen, C.‐H. / Hsu, Y.‐C. / Lu, S.‐N. / Hung, C.‐H. / Wang, J.‐H. / Lee, C.‐M. / Hu, T.‐H. et al. | 2018
- 598
-
Improved performance of quantitative collagen parameters versus standard histology in longitudinal assessment of nonadvanced liver fibrosis for chronic hepatitis bWang, Y. / Liang, X. / Yang, J. / Wang, H. / Tan, D. / Chen, S. / Cheng, J. / Chen, Y. / Sun, J. / Rong, F. et al. | 2018
- 608
-
Low incidence of hepatitis b virus reactivation and subsequent hepatitis in patients with chronic hepatitis c receiving direct‐acting antiviral therapyTamori, A. / Abiru, S. / Enomoto, H. / Kioka, K. / Korenaga, M. / Tani, J. / Enomoto, M. / Sugiyama, M. / Masaki, T. / Kawada, N. et al. | 2018
- 620
-
Hepatitis C eradication with DAA and risk of liver cancer recurrence: The debate unrestsColombo, M. / Boccaccio, V. et al. | 2018
- 623
-
Increased recurrence rates of hepatocellular carcinoma after DAA therapy in a hepatitis C‐infected Egyptian cohort: A comparative analysisEl Kassas, M. / Funk, A. L. / Salaheldin, M. / Shimakawa, Y. / Eltabbakh, M. / Jean, K. / El Tahan, A. / Sweedy, A. T. / Afify, S. / Youssef, N. F. et al. | 2018
- 631
-
Efficacy and safety of 6 or 8 weeks of simeprevir, daclatasvir, sofosbuvir for HCV genotype 1 infectionSulkowski, M. S. / Feld, J. J. / Lawitz, E. / Felizarta, F. / Corregidor, A. M. / Khalid, O. / Ghalib, R. / Smith, W. B. / Van Eygen, V. / Luo, D. et al. | 2018
- 640
-
Uptake of direct‐acting antiviral treatment for chronic hepatitis C in AustraliaHajarizadeh, B. / Grebely, J. / Matthews, G. V. / Martinello, M. / Dore, G. J. et al. | 2018
- 649
-
Development of a recombinant murine tumour model using hepatoma cells expressing hepatitis C virus nonstructural antigensYoung, K. G. / Haq, K. / MacLean, S. / Dudani, R. / Elahi, S. M. / Gilbert, R. / Weeratna, R. D. / Krishnan, L. et al. | 2018
- 661
-
Treatment of HCV infection in Poland at the beginning of the interferon‐free era—the EpiTer‐2 studyFlisiak, R. / Zarębska‐Michaluk, D. / Janczewska, E. / Staniaszek, A. / Gietka, A. / Mazur, W. / Tudrujek, M. / Tomasiewicz, K. / Belica‐Wdowik, T. / Baka‐Ćwierz, B. et al. | 2018
- 670
-
Characterizing the temporal evolution of the hepatitis C virus epidemic in PakistanAyoub, H. H. / Al Kanaani, Z. / Abu‐Raddad, L. J. et al. | 2018
- 680
-
Assessing hepatitis C spontaneous clearance and understanding associated factors—A systematic review and meta‐analysisAisyah, D. N. / Shallcross, L. / Hully, A. J. / O'Brien, A. / Hayward, A. et al. | 2018
- 699
-
Impact of interferon‐free regimens on the glomerular filtration rate during treatment of chronic hepatitis C in a real‐life cohortÁlvarez‐Ossorio, M. J. / Sarmento e Castro, R. / Granados, R. / Macías, J. / Morano‐Amado, L. E. / Ríos, M. J. / Merino, D. / Álvarez, E. N. / Collado, A. / Pérez‐Pérez, M. et al. | 2018
- 707
-
Entecavir and tenofovir reduce hepatitis B virus‐related hepatocellular carcinoma recurrence more effectively than other antiviralsCho, H. / Ahn, H. / Lee, D. H. / Lee, J.‐H. / Jung, Y. J. / Chang, Y. / Nam, J. Y. / Cho, Y. Y. / Cho, E. J. / Yu, S. J. et al. | 2018
- 718
-
Occult HBV infection in HIV‐infected adults and evaluation of pooled NAT for HBVDinesha, T. R. / Boobalan, J. / Sivamalar, S. / Subashini, D. / Solomon, S. S. / Murugavel, K. G. / Balakrishnan, P. / Smith, D. M. / Saravanan, S. et al. | 2018